作为向放射性核酸治疗的共价蛋白增强抗瘤效果
Paul C Klauser1,2, Shalini Chopra1,2,3, Li Cao1,2
1Department of Pharmaceutical Chemistry and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, California 94158, United States.
ACS central science
|July 3, 2023
概括
这项研究引入了癌症的第一个共价蛋白放射性核素疗法 (TRT). 这种新的方法通过形成不可逆转的纽带来提高瘤向和疗效,提高安全性和治疗结果.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 放射性药物化学 放射性药物化学
背景情况:
- 分子向放射性核素疗法 (TRT) 在平衡瘤向有效性与正常组织安全性方面面临挑战.
- 目前的TRT策略往往会损害药物的药理动力学,并增加正常组织的辐射,由于延长循环增强瘤吸收.
研究的目的:
- 开发一种新型的共价蛋白TRT,可以增强瘤放射性同位素的积累和保留,而不会改变药物动力学特征或正常组织生物分布.
- 与其非共价对应物相比,研究基于共价纳米体的TRT的有效性和安全性.
主要方法:
- 通过使用遗传密码扩展设计了一种含有潜在生物反应性氨基酸的纳米体.
- 工程纳米体在结合时与其标蛋白形成不可逆转的共价链接,靠近距离激活的反应性使之成为可能.
- 在瘤模型中的体外,细胞和体内研究中,用actinium-225对共价纳米体进行放射标记.
主要成果:
- 同价纳米体在体外,癌细胞和体内瘤中证明了目标蛋白质的不可逆转的交叉链接.
- 放射性标记的共价纳米体显著增加了放射性同位素水平和瘤中的停留时间,同时保持了快速的全身清除.
- 与225-actinium的共价纳米体的结合导致优异的瘤生长抑制与非共价纳米体相比,没有可观察到的组织毒性.
结论:
- 第一个共价蛋白TRT的开发代表了癌症治疗的重大进步.
- 这种化学策略通过增强放射性同位素的输送和保留来改善瘤对TRT的反应,提供了更安全,更有效的治疗方式.
- 共价方法是可扩展的,适用于针对不同瘤抗原的广泛的蛋白质放射性药物.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drug-Receptor Bonds
3.0K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
3.0K
Covalently Linked Protein Regulators
6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.9K
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573


